NASD · Healthcare · Biotechnology · USA
AnaptysBio Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
AnaptysBio Inc is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes rosnilimab for rheumatoid arthritis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for various inflammatory conditions. The company also receives revenue from royalties and milestones under collaborations with GSK and Vanda Pharmaceuticals for previously out-licensed therapeutic antibodies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the AnaptysBio Inc stock.
Undervalued: intrinsic value $87.41 per share, market price $45.43, margin of safety 48.0% (as of 2026-10-20).
Discounting its cash flows at 8.8% (average of 3 methods) values the shares at $87.41; the price of $45.43 is 48% below that value, and 78% of that value comes from beyond year five.
Leak Score: 87/100 on 9 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
7 more in this industry show a wider margin of safety.
ANAB is undervalued (as of the 2026-10-20 close). Discounting its cash flows at 8.8% (average of 3 methods) values the shares at $87.41; the price of $45.43 is 48% below that value, and 78% of that value comes from beyond year five.
$87.41 per share (as of the 2026-10-20 close), against a market price of $45.43. That is a margin of safety of 48.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
87 out of 100, which we rate "Strong Leak", on 9 of 12 value investing signals.